Search research articles
Contact Us
Filters
Showing results (91-100 of 146) with videos related to
Page
of 15
Sort By:
Trials
|
June 13, 2009
Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial
Matthew R Sydes, Mahesh K B Parmar, Nicholas D James, et al.
Journal of the National Cancer Institute
|
May 17, 2007
Oral sodium clodronate for nonmetastatic prostate cancer--results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873)
Malcolm D Mason, Matthew R Sydes, John Glaholm, et al.
Journal of the National Cancer Institute
|
September 4, 2003
A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial)
David P Dearnaley, Matthew R Sydes, Malcolm D Mason, et al.
BJU International
|
July 15, 2016
Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life
Athene Lane, Chris Metcalfe, Grace J Young, et al.
Journal of Translational Medicine
|
August 28, 2015
YangZheng XiaoJi exerts anti-tumour growth effects by antagonising the effects of HGF and its receptor, cMET, in human lung cancer cells
Wen G Jiang, Lin Ye, Fiona Ruge, et al.
The Lancet. Oncology
|
August 29, 2014
Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial
J Athene Lane, Jenny L Donovan, Michael Davis, et al.
BJU International
|
February 3, 2015
Final quality of life and safety data for patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (EAP) (NCT01254279)
Amit Bahl, Susan Masson, Zafar Malik, et al.
BJU International
|
November 8, 2008
Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial
Nicholas D James, Matthew R Sydes, Noel W Clarke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 28, 2015
Impact of Radiotherapy When Added to Androgen-Deprivation Therapy for Locally Advanced Prostate Cancer: Long-Term Quality-of-Life Outcomes From the NCIC CTG PR3/MRC PR07 Randomized Trial
Michael Brundage, Matthew R Sydes, Wendy R Parulekar, et al.
Anticancer Research
|
March 10, 2015
Expression of Sonic Hedgehog (SHH) in human lung cancer and the impact of YangZheng XiaoJi on SHH-mediated biological function of lung cancer cells and tumor growth
Wen G Jiang, Lin Ye, Fiona Ruge, et al.
Page
of 15
Search research articles
Search
Showing results (91-100 of 146) with videos related to
Sort By:
Page
of 15
Trials
|
June 13, 2009
Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial
Matthew R Sydes, Mahesh K B Parmar, Nicholas D James, et al.
Journal of the National Cancer Institute
|
May 17, 2007
Oral sodium clodronate for nonmetastatic prostate cancer--results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873)
Malcolm D Mason, Matthew R Sydes, John Glaholm, et al.
Journal of the National Cancer Institute
|
September 4, 2003
A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial)
David P Dearnaley, Matthew R Sydes, Malcolm D Mason, et al.
BJU International
|
July 15, 2016
Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life
Athene Lane, Chris Metcalfe, Grace J Young, et al.
Journal of Translational Medicine
|
August 28, 2015
YangZheng XiaoJi exerts anti-tumour growth effects by antagonising the effects of HGF and its receptor, cMET, in human lung cancer cells
Wen G Jiang, Lin Ye, Fiona Ruge, et al.
The Lancet. Oncology
|
August 29, 2014
Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial
J Athene Lane, Jenny L Donovan, Michael Davis, et al.
BJU International
|
February 3, 2015
Final quality of life and safety data for patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (EAP) (NCT01254279)
Amit Bahl, Susan Masson, Zafar Malik, et al.
BJU International
|
November 8, 2008
Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial
Nicholas D James, Matthew R Sydes, Noel W Clarke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 28, 2015
Impact of Radiotherapy When Added to Androgen-Deprivation Therapy for Locally Advanced Prostate Cancer: Long-Term Quality-of-Life Outcomes From the NCIC CTG PR3/MRC PR07 Randomized Trial
Michael Brundage, Matthew R Sydes, Wendy R Parulekar, et al.
Anticancer Research
|
March 10, 2015
Expression of Sonic Hedgehog (SHH) in human lung cancer and the impact of YangZheng XiaoJi on SHH-mediated biological function of lung cancer cells and tumor growth
Wen G Jiang, Lin Ye, Fiona Ruge, et al.
Page
of 15